Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease

By Cheng Steven   Coyne Daniel  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 5, 2006-04 ,pp. : 617-621

Informa Healthcare

Access to resources Recommend Favorite

Use of Enoxaparin in Patients with Chronic Kidney Disease: Safety Considerations

By Brophy Donald F.   Sica Domenic A.  

Drug Safety, Vol. 30, Iss. 11, 2007-01 ,pp. : 991-994

Adis International

Access to resources Recommend Favorite

Comparative Cost-Benefit Analyses of Paricalcitol and Calcitriol in Stage 4 Chronic Kidney Disease from the Perspective of a Health Plan

By Gal-Moscovici Anca  

Clinical Drug Investigation, Vol. 27, Iss. 2, 2007-01 ,pp. : 105-113

Adis International

Access to resources Recommend Favorite

Beneficial Effects of Selective Vitamin D Receptor Activation by Paricalcitol in Chronic Kidney Disease

By  

Current Drug Targets, Vol. 15, Iss. 7, 2014-06 ,pp. : 703-709

Bentham Science Publishers

Access to resources Recommend Favorite

Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease

By Del Vecchio Lucia   Locatelli Francesco  

Expert Opinion on Drug Safety, Vol. 11, Iss. 6, 2012-11 ,pp. : 923-931

Informa Healthcare

Access to resources Recommend Favorite